Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC
Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).
Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that is used to predict 12-week survival rates for patients with colorectal cancer (CRC).
Pietrantonio explains that the nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks.
Additionally, the nomogram can be used as a prognostication method for patient selection, as some of these high-risk patients are enrolled on clinical trials.
